Revolution Medicines, Inc. (RVMD)
NASDAQ · Healthcare · Biotechnology
Profile
Revolution Medicines, Inc.
- Exchange
- NASDAQ
- Ticker
- RVMD
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- US
Revolution Medicines, Inc. is a precision oncology firm operating in the clinical development stage, dedicated to creating innovative treatments that target novel pathways crucial for RAS-driven cancers. Its pipeline includes several promising drug candidates: RMC-4630, an SHP2 inhibitor, is currently undergoing Phase 1/2 clinical trials for various solid tumors, such as gynecological and colorectal cancers. The company's portfolio also features RMC-5845, a selective inhibitor designed to target SOS1, a protein responsible for activating RAS within cells, and RMC-5552, a highly selective inhibitor for hyperactive mTORC1 signaling found in cancerous cells. Further expanding its therapeutic arsenal, Revolution Medicines is advancing RMC-6291, which selectively inhibits mutated forms of KRASG12C(ON) and NRASG12C(ON). Another promising compound, RMC-6236, specifically targets and inhibits a range of active RAS(ON) variants. Its research efforts also encompass other active RAS inhibitors aimed at KRASG13C(ON) and KRASG12D(ON) mutations. Revolution Medicines has established a collaborative partnership with Sanofi to research and develop SHP2 inhibitors, a collaboration that includes the development of RMC-4630. Established in 2014, Revolution Medicines, Inc. operates from its corporate headquarters situated in Redwood City, California.
Key facts
Revolution Medicines, Inc.: key facts
- Revolution Medicines, Inc. (NASDAQ: RVMD) is a Biotechnology company in the Healthcare sector.
- In fiscal 2025, Revolution Medicines, Inc. reported revenue of $0.0 and net income of -$1.1B.
- Free cash flow was positive in 0 of the last 5 fiscal years.
- Net income was positive in 0 of the last 5 fiscal years.
- Over the last twelve months, revenue was $197.6M and net income was -$1.9B.
MonkScore
Revolution Medicines, Inc.'s MonkScore
MonkScore
MonkScore range: 20–29
as of November 2026
Sector rank: 493 of 632 in Healthcare
How this score is madeDisclaimer
Pillar ranges
- Growth30–39
- Profitability50–59
- Quality10–19
- Market Conviction90–100
- Safety70–79
The MonkScore runs from 0 to 100. Each range is one of ten 10-point groups, from 0–9 to 90–100.
Each pillar's range uses the same ten groups. The exact score and the pillar scores are in the MonkStreet app.
Fundamentals
Figures from the statements
Revolution Medicines, Inc.'s annual figures and the last twelve months, in USD. Last report: 30 September 2026.
| Figure | Last 12 months | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Revenue | $197.6M | $0.0 | $0.0 | $11.6M | $35.4M | $29.4M |
| Gross profit | $188.0M | -$16.6M | $0.0 | $11.6M | $35.4M | $29.4M |
| Operating income | -$1.7B | -$1.2B | -$689.5M | -$487.2M | -$258.3M | -$188.0M |
| Net income | -$1.9B | -$1.1B | -$600.1M | -$436.4M | -$248.7M | -$187.1M |
| Operating cash flow | -$1.4B | -$897.7M | -$557.4M | -$350.6M | -$224.4M | -$147.2M |
| Capital expenditure | -$9.4M | -$16.0M | -$10.3M | -$7.7M | -$10.8M | -$6.5M |
| Free cash flow | -$1.4B | -$913.7M | -$567.7M | -$358.3M | -$235.2M | -$153.7M |
| Total debt | $639.1M | $158.7M | $135.8M | $87.9M | $64.2M | $66.6M |
| Cash | $615.9M | $383.7M | $543.1M | $696.1M | $161.4M | $108.5M |
Revenue growth a year
- 1-year
- —
- 3-year
- —
- 4-year
- —
Compound growth between fiscal years.
Peers
Similar companies
- Oruka Therapeutics, Inc.NASDAQ:ORKAMonkScore range: 20–29
- uniQure N.V.NASDAQ:QUREMonkScore range: 30–39
- Ionis Pharmaceuticals, Inc.NASDAQ:IONSMonkScore range: 30–39
- Regeneron Pharmaceuticals, Inc.NASDAQ:REGNMonkScore range: 30–39
- ACADIA Pharmaceuticals Inc.NASDAQ:ACADMonkScore range: 30–39
- REGENXBIO Inc.NASDAQ:RGNXMonkScore range: 30–39
- Recursion Pharmaceuticals, Inc.NASDAQ:RXRXMonkScore range: 30–39
- BioMarin Pharmaceutical Inc.NASDAQ:BMRNMonkScore range: 30–39
Score my top stocks · 14-day free trial · card required · not charged during the trial · cancel in one click
MonkStreet provides research, not investment advice.
Page built on 11 November 2026.